Download - Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

Transcript
Page 1: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

Inflammatory bowel disease & liver disease• Primary sclerosing cholangitis or autoimmune hepatitis

develop in– 3-10% of patients with IBD– 70% of patients with PSC suffer from IBD– Broome et al Dis Col Rec 1995; Loftus Gut 2005

IBD PSC

Page 2: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

Extraintestinal Manifestations of inflammatory bowel disease

Joints•Type 1 and 2 Arthropathy

•Orchard, Wordsworth and Jewell•Ankylosing spondylitis

Liver•Primary sclerosing cholangitis•Autoimmune hepatitis

Eye•Uveitis•Iritis•Episcleritis

Skin•Erythema Nodosum•Pyoderma Gangrenosum

Broome U et al. Gut 1996Chapman,R.W. Gut 1991

Page 3: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

Diseases associated with

active bowel disease

Pyoderma gangrenosum

Pyoderma gangrenosum

Erythema nodosum

Episcleritis

Page 4: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

Liver disease runs a course that is independent of bowel disease

•PSC can develop after colectomy for UC•UC can develop after liver transplant for PSC

Page 5: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

What is the Link?ENTEROHEPATIC RECIRCULATION OF

LYMPHOCYTES– Lymphocytes primed in the gut

recirculate through the liver

– Memory cells are long-lived and will continue to recirculate for many years

– The chance of responding subsequently to modified-self or foreign antigens in the liver is increased

Page 6: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

Thymus Naïve T cells -CD45RA+,CCR7+, LFA-1low

Lymph node

Activated T cells -CD45RO+,CCR7-

TISSUE SPECIFC HOMING RECEPTORS

Long-lived Memory cellsCD45RA+ LFA-1high

TISSUE SPECIFIC HOMING RECEPTORS

Target Organ –Liver or Gut

DC

DC

DC – Dendritic Cells

Antigens

•Antigen recognition

•Lymphocyte activation

•Tissue specific homing molecules

Thymocytes

Page 7: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

SIGNAL 1TetheringSelectins

SIGNAL 2Trigger

ChemokineSIGNAL 3

ArrestIntegrins

SIGNAL 4Transmigration

IntegrinsJAMs

Chemokine

Migration and retention in tissue

IntegrinsChemokine

Page 8: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

HEV CCL21 CCR7

Stroma of LN

Comment

CCL19CCR7

Chemokine ligandsChemokine receptor

CCL21 attached to GAGs

High Endothelial Venule

PNAd

Lymphocyte

CCR7

Naïve T cell homes to lymph node

ICAM-1

L-selectin

αLβ2 (LFA-1)

Page 9: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

Skin vesselsCCL17 CCR4

CommentChemokine ligands

CCL17 attached to GAGs

Endothelial cell

E-selectin

Lymphocyte

CCR4

Skin Homing memory T cells

CLA

αLβ2

ICAM-1

Page 10: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

MAdCAM-1 A GUT ADDRESSIN

COOH

SS

SS

SS

SS

GUTColon & small bowel LP/submucosal endotheliumAppendicitis HEV endotheliumCD & UC LP/submucosal endotheliumMLN HEV endothelium

Lung, liver, kidney, heart Negative

Briskin Am J Path 1997

Page 11: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

MAdCAM-1 A GUT ADDRESSIN

T Cellα4β7

COOH

SS

SS

SS

SS

GUTColon & small bowel LP/submucosal endotheliumAppendicitis HEV endotheliumCD & UC LP/submucosal endotheliumMLN HEV endothelium

Lung, liver, kidney, heart Negative

Berlin et al Cell 1993

Page 12: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

Small bowel

Comment

CCL25CCR9

Chemokine ligandsChemokine receptor

CCL25

Endothelial cell

VCAM-1

Lymphocyte

Integrins

CCR9

Gut Homing T cellSvensson et al J Clin Invest 2003Kunkel et al J Exp Med 2000

α4β1α4β7

MAdCAM-1

CCL25 confined to thymus and small bowelRecruits CCR9+ T cells & IgA secreting B cells

Kunkel et al J Exp Med 2000, Zabel et al Ibid 1999

Page 13: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

VCAM-1

α4β1

MAdCAM-1

α4β7 CLA

E-selectin

αLβ2

ICAM-1

Small bowel homing lymphocytesMora JR et al. Nature 2003.

Skin homing lymphocytesCampbell JJ et al Nature 2001.

L-selectin

Peripheral node addressin

αLβ2

ICAM-1

Lymph node homing Naïve T cells

CCR7

CCR4CCR9

Page 14: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

Selective imprinting of gut-homing T cells by Peyer’s patch dendritic cells

J. Rodrigo Mora et al Nature 2003Peyer’s Patch DCs imprint gut homing on responding T cells

whereas DCs from spleen or PLN cannot

Gut dendritic cells induce expression of α4β7 on T cellsStagg et al Eur J Immunol 2003

What drives the unique homing phenotype of mucosal T cells?

Selective generation of gut tropic T cells in gut-associated lymphoid tissue

B. Johansson-Lindbom,B J Exp. Med 2003

Page 15: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

Retinoic acid imprints gut-homing specificity on T cellsIwata M, Hirakiyama A, Eshima Y, Kagechika H, Kato C, Song SY.Immunity Oct 2004

•Retinoic acid, enhances expression of α4β7 and CCR9 on T cells and imprints them with gut tropism.

•Vitamin A deficiency causes a reduction in α4β7 memory T cells in lymphoid organs and intestinal lamina propria.

Novel role for retinoic acid in imprinting gut-homing specificity on T cells

Page 16: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

Vitamin A deficiency is associated with gut infections and chronic diarrhoea

Page 17: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

Retinoic acid imprints gut-homing specificity on T cellsIwata M et al Immunity Oct 2004

Retinal Retinol Retinoic acid

ADHRetinal

dehydrogenase

Page 18: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

Retinoic acid imprints gut-homing specificity on T cellsIwata M et al Immunity Oct 2004

Retinal Retinol Retinoic acid

ADHRetinal

dehydrogenaseSelectively expressed

in gut DCs

Page 19: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

Retinoic acid imprints gut-homing specificity on T cellsIwata M et al Immunity Oct 2004

Retinal Retinol Retinoic acid

ADHRetinal

dehydrogenase

RARRetinoic acid

receptors

Selectively expressed in gut DCs

Page 20: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

Retinoic acid imprints gut-homing specificity on T cellsIwata M et al Immunity Oct 2004

Retinal Retinol Retinoic acid

RA-responsive enhancer sequence

CCR9

ADHRetinal

dehydrogenase

RARRetinoic acid

receptors

3p21.3

β7 Chromosome 15

Selectively expressed in gut DCs

Page 21: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

MLN DC71%Unstimulated8.8%Isotype matched control mab

CC

R9

Activation of CD3+ PBL at 7 days

CD3/CD28 100nM ATRA

66.4%

(52.6)

Generation of Gut-Homing IgA-Secreting B Cells by Intestinal Dendritic Cells

Mora, Eksteen et al Science Nov 18 2006

DCs from human mesenteric LN imprint CCR9 on responding lymphocytes

Page 22: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

MLN

MAdCAM-1

α4β7

CCR9

Page 23: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

VAP-1

MAdCAM-1

α4β7

CCR9

MLN

PORTAL LN

MAdCAM-1 in PSC

Grant,A.J. et al. 2001. Hepatology.

MADCAM-1

Page 24: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

MAdCAM-1

MAdCAM-1

CCL25

α4β7

CCR9

MLN

CCL25 confined to thymus & small bowel

•Critical for recruiting CCR9+ T cells and IgAsecreting B cells to the small bowel

Kunkel et al J Exp Med 2000; Zabel et al Ibid 1999

CCR9 and a4b7 are selectively expressed on mucosal lymphocytes

Papadakis Gastro 2001

CCL25

Page 25: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

MAdCAM-1

MAdCAM-1

CCL25

α4β7

CCR9

MLN

CCL25 upregulated on endothelium only in PSC and autoimmune hepatitisEksteen et al J Exp Med 2004

CCL25

MergedCCL25

CD31

Page 26: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

In PSC 20% of liver lymphocytes express CCR9

+

0 20 40 60 80 100Mean % CCR9+ T-cells

CD LPL n=3CD PBL n=3

NL LIL n=6N PBL n=6

PBC LIL n=6PSC PBL n=8PSC LIL n=8

Page 27: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

α4β7

CC

R9

PSC LIL 17%

In PSC 20% of liver lymphocytes express CCR9

+

0 20 40 60 80 100Mean % CCR9+ T-cells

CD LPL n=3CD PBL n=3

NL LIL n=6N PBL n=6

PBC LIL n=6PSC PBL n=8PSC LIL n=8

Page 28: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

α4β7

CC

R9

PSC LIL 17%

In PSC 20% of liver lymphocytes express CCR9

+

0 20 40 60 80 100Mean % CCR9+ T-cells

CD LPL n=3CD PBL n=3

NL LIL n=6N PBL n=6

PBC LIL n=6PSC PBL n=8PSC LIL n=8

PBL

IFNγ

PHA 0hrs

PHA 0hrs

PHA 4hrs

PHA 4hrs

1%

13%

78%

2%

These are primed T cells

Page 29: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

VCAM-1 MAdCAM-1

α4β1

α4β7

CCR9

VCAM-1

α4β1

α4β7

MAdCAM-1

Endothelial cellGut homing lymphocytes PSC Liver infiltrating lymphocytes

VAP-1R

VAP-1

VAP-1R

CCR9

CCL25CCL25

Page 30: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

VCAM-1 MAdCAM-1

α4β1

α4β7

CCR9

VCAM-1

α4β1

α4β7

MAdCAM-1

Endothelial cellGut homing lymphocytes PSC Liver infiltrating lymphocytes

VAP-1R

VAP-1

VAP-1R

CCR9

CCL25CCL25

Where are gut-homing T cells in PSC imprinted?

In the liver or the gut?

Page 31: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

Neo lymphogenesis is seen in portal-associated lymphoid follicles in PSC

CCL21 on HEV

CCL19 on lymphatics and stromal cells

Grant et al Am J Path 2002

Page 32: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

Isolation of DCs from PSC liver tissue Goddard et al Am J Pathol 2004

Fresh liver pieces incubated over night at 37OC in RPMI 10% FCS

Immunomagnetic selection to deplete CD3 and enrich CD11c

DCs matured with LPS and used at 1:5 ratio to activate naïve

allogeneic T cells +/- 10nM ATRA

CCR9 and α4β7 expression measured day 0,3,7,14

Can PSC liver-derived DCs imprint CCR9 and α4β7 on responding T cells?

Page 33: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

CD3

CCR9 expression

Can Liver Dendritic Cells induce Gut Homing Molecules ?

Mora, Iwata, Eksteen et al.  Science 2006

Page 34: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

VCAM-1 MAdCAM-1

α4β1 α4β7

CCR9

VCAM-1

α4β1

α4β7

MAdCAM-1

Endothelial cellGut homing lymphocytes PSC Liver infiltrating lymphocytes

VAP-1R

VAP-1

VAP-1R

CCR9

CCL25CCL25

DCs from human liver CANNOT imprint CCR9 on responding lymphocytes

Page 35: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

VCAM-1 MAdCAM-1

α4β1 α4β7

CCR9

VCAM-1

α4β1

α4β7

MAdCAM-1

Endothelial cellGut homing lymphocytes PSC Liver infiltrating lymphocytes

VAP-1R

VAP-1

VAP-1R

CCR9

CCL25CCL25

CCR9+ T cells in the liver are mucosal T cells imprinted by gut DC

DCs from human liver CANNOT imprint CCR9 on responding lymphocytes

Page 36: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

What retains T cells in the liver?

Red = HEA 125

Green = CD45

Page 37: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

CCL28 and CCR10• CCL28 expressed in mucosal epithelium

– Pan et al J Immunol 2004• CCR10 expressed by IgA secreting B cells

– Kunkel JCI 2003

• CCL28 is expressed on inflamed bile ducts

Page 38: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

20% Liver infiltrating T cells express CCR10

Human cholangiocytes secrete CCL28 in response to LPS and IL-1

Spleen Blood NLiver Inflamed liver

Page 39: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

VCAM-1 expression on bile ducts and cholangiocytes

TNFαTNFα

Control Control

Liver infiltrating lymphocytes bind to cholangiocytes via VCAM1 when activated by chemokines

Heydtmann et al J Immunol 2005

Page 40: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

Activated Caspase 3 in PSC LIL cultured on plastic with IL-2 at 12Hrs

Biliary epithelial cell (BEC) rescue of LIL from apoptosis

Page 41: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

Activated Caspase 3 in PSC LIL cultured on plastic with IL-2 at 12Hrs

Biliary epithelial cell (BEC) rescue of LIL from apoptosis

VCAM-1 on bile ducts

VCAM-1 on TNFα treated cholangiocytes

TNFα

Control

Page 42: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

Activated Caspase 3 in PSC LIL cultured on plastic with IL-2 at 12Hrs

Biliary epithelial cell (BEC) rescue of LIL from apoptosis

Activated Caspase 3 in PSC LIL cultured on TNFα stimulated fixed BEC 12Hrs with IL-2

VCAM-1 on bile ducts

VCAM-1 on TNFα treated cholangiocytes

TNFα

Control

Page 43: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

VCAM-1 MAdCAM-1

α4β1α4β7

CCR9

PSC Liver endothelium

PSC Biliary epithelial cell

VAP-1

VAP-1R

CCL25

CCR10

VCAM-1

CCR9

CCL28

α4β1

VAP-1R

CCR10

CCR9 & CCL25 specific to PSC

PROMOTES RECRUITMENT

CCR10 & CCL28 Target cells to bile ducts

Eksteen et al J Immunol 2006

Page 44: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

IBD

Naïve T cell

MLN + PPs

Page 45: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

α4β7

Naïve T cell

Effector T cellVAP-1r

MLN + PPs

CCR-9 CXCR3

Page 46: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

IBD

α4β7

Liver endothelium Gut endotheliumVAP-1, MAdCAM-1 MAdCAM VAP-1

CCL25, CXCR3

Naïve T cell

VAP-1r

MLN + PPs

CCR-9 CXCR3

Page 47: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

IBD

α4β7

Naïve T cell

Memory T cell

VAP-1r

MLN + PPs

CCR-9

Liver endothelium Gut endotheliumVAP-1, MAdCAM-1 MAdCAM

CCL25, CCL28

Page 48: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

GUT

α4β7

Liver endothelium Gut endotheliumVAP-1, MAdCAM-1 MAdCAM

NO antigen

NO retention

release to lymphatics

RECIRCULATION

Naïve T cell

Memory T cellVAP-1r

MLN + PPs

α4β7VAP-1r

Page 49: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

Naïve T cell

Memory T cell

MLN + PPs

+antigen

activation

retention

INFLAMMATION

α4β7VAP-1r

CCR-9

α4β7VAP-1r

CCR9

GUT

VAP-1, MAdCAM-1 MAdCAM

Page 50: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

Naïve T cell

Memory T cell

MLN + PPs

GUT

Liver endothelium Gut endotheliumMAdCAM-1 CCL25 MAdCAM, VAP-1

α4β7VAP-1r

MAdCAMCCL25CCL28

CCR9

+antigen

activation

retention

INFLAMMATION

α4β7VAP-1r

CCR9 CXCR3

Page 51: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

CREDITS

CollaboratorsSirpa Jalkanen and Marko Salmi (Turku)Ron Gladue and Nick Pullen (Pfizer)Mike Briskin (Millenium)Uli von Andrian and Rodrigo Mora (Harvard)

THE UNIVERSITY OF BIRMINGHAMBirmingham

Liver Labs

Bertus EksteenAllister GrantTrish Lalor

Stuart CurbishleyAlice MilesChris Weston

Dept Pathology Stefan Hubscher

Page 52: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

DCs from human liver imprint low levels of α4β7 on responding lymphocytes

*p<0.05; **p<0.01

Page 53: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

CD3

CCR9

Anti-CD28+anti-CD3

antiCD28+CD3+ATRA 100nm

ControlCD28+CD3CD28+CD3+ATRA 100nM

CCR9 Day 7

Day 0 Day3 Day7

%C

CR

9

Human Tcellsactivated in the presence of vitamin A upregulate CCR9

Eksteen et al 2007

Page 54: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

Adams et al. Nature Reviews Immunology 6, 244–251 (March 2006) | doi:10.1038/nri1784

The hepatic sinusoids are a unique, low-flow vascular bed

Page 55: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

Constitutively expressed in the liver Supports lymphocyte recruitment McNab Gastro 1996; Lalor J Immunol 2002; Bonder et al Immunity 2005

Vascular adhesion protein 1 promotes lymphocyte recruitment to the liver

ContactArrest

Extravasation

Sinusoidal endothelium

VELOCITYVAP-1

ICAM-1 VAP-1

VAP-1 in normal human liver

Page 56: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

PSC PSC

CCL25 is over-expressed in PSC livers

PSC NL BAT ALD PBC SKIN

Fold

incr

ease

in C

CL2

5 m

RN

A

MergedCCL25

CD31

Eksteen et al J Exp Med 2004

1 2 3 4 5 6 1 2 3 1 2 3 4 1 2 3 4Primary sclerosing cholangitis Alc cirrhosis Primary biliary cirrh Other CLD

14 kDa -

Page 57: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

CCR9 INDUCTION IS LOST FOLLOWING RESTIMULATION WITH HUMAN LIVER-

DERIVED DCs

Page 58: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

Chronic hepatitis

Resolution

Cirrhosis

PSC•Virus/infection•Toxin•Autoimmunity

CD3Bile duct fibrosis

CIRRHOSIS AND CHOLANGIOCARCINOMA

Page 59: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

Chronic hepatitis

Resolution

Cirrhosis

PSC•Virus/infection•Toxin•Autoimmunity

CD3Bile duct fibrosis

CIRRHOSIS AND CHOLANGIOCARCINOMA

Page 60: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

VAP-1

MAdCAM-1

VAP-1L αLβ2

CXCR3

α4β7

CCR9

MLN

PORTAL LN

Page 61: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

VAP-1

MAdCAM-1

VAP-1L αLβ2

CXCR3

PORTAL LN

VAP-1 in IBD

Salmi M et al 1994 Gastroenterology

VAP-1

Grant AJ et al 2001 Hepatology

Page 62: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

VCAM-1MAdCAM-1

VAP-1 ICAM-1

Small bowel homing lymphocytesKunkel 2000, Papadakis 2001; Svensson 2002.

Liver homing effector lymphocytes

L-selectin

Peripheral node addressin

αLβ2

ICAM-1

Lymph node homing Naïve T cells

CCR7

VAP-1L αLβ2

CXCR3

α4β1 α4β7

CCR9

Page 63: Inflammatory bowel disease & liver disease - Dr. Falk Pharma · Inflammatory bowel disease & liver disease • Primary sclerosing cholangitis or autoimmune hepatitis develop in –

DCs from human mesenteric LN but not those from human liver imprint CCR9 on responding lymphocytes

RAR-pan-antagonist LE540

RARα−agonist Am580

*p<0.05; **p<0.01